Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06915454 · ClinicalTrials.gov registry record · NA

High-Resolution PET-CT Imaging for Surgical Margin Visualization

A NA study of Cancer and HNSCC, sponsored by Vanderbilt-Ingram Cancer Center.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06915454: Recruiting NA study of Cancer and HNSCC, sponsored by Vanderbilt-Ingram Cancer Center.

NCT06915454 is a NA study of Cancer and HNSCC that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06915454, a NA study of Cancer and HNSCC, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature of device use. Of note, the surgical resection will proceed as per standard of care and will not be affected by the research protocol. Potential Benefit: Imaging intra-operatively will ensure surgeons to identify at risk resection margins. Time Commitment: There are no additional visits that will be asked of you to partake in this study. Drug is FDA approved and Exposure to Radiation is minimal.

Primary Outcome

This study is an exploratory pilot study where the main goal is to gather scientific knowledge. Since no results with a certain significance need to be proven, no power analysis will be performed. Pre-Surgery Preparation: Patients are injected with a PET (18F-FDG) tracer. This tracer highlights cancerous tissues by emitting signals detectable by PET imaging. Intraoperative Imaging: Once the tumor is removed, the specimen is scanned using the XEOS Aura 10 device in the operating room. This allo

Interventions

  • DEVICE Intra-op PET/CT Specimen Scanner

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-09-03
Est. Completion 2027-07
Phase NA
Vanderbilt-Ingram Cancer Center

189 total trials

What NCT06915454 shows while recruiting

NCT06915454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Intra-op PET/CT Specimen Scanner is the first listed.

NCT06915454 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT06915454 about?

NCT06915454 is a clinical study titled "High-Resolution PET-CT Imaging for Surgical Margin Visualization". Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature of device use. Of note, the surgical resection will proceed as per stand...

What is the current status of trial NCT06915454?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-09-03. Estimated completion is 2027-07.

What conditions does trial NCT06915454 study?

This clinical trial studies the following conditions: Cancer, HNSCC, SCC - Squamous Cell Carcinoma, HNSCC,Larynx, Pharynx and Oral Cavity, Solid Malignant Tumors.

What interventions are being tested in trial NCT06915454?

The interventions under investigation include: Intra-op PET/CT Specimen Scanner (DEVICE).

Who is sponsoring clinical trial NCT06915454?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06915454 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06915454's enrollment target sits among peer trials

50 422nd of 615 higher than 179 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06915454, the US trial registry maintained by the National Library of Medicine. NCT06915454 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.